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1. Introduction
In 2003, the South African Heart Association (SA Heart) and the 
Lipid and Atherosclerosis Society of Southern Africa (LASSA) 
officially adopted the European Guidelines for the Prevention of 
Cardiovascular Disease1 to replace the South African Lipid Guidelines 
published in 2000.2 The European document has recently been 
updated with the publication of the European Society of Cardiology 
(ESC)/European Society of Atherosclerosis (EAS) Guideline for the 
Management of Dyslipidaemias in 2011.3 This Consensus Statement 
promotes current best management of dyslipidaemia and should be 
adopted by all health care professionals in South Africa. 
South Africa is a multi-ethnic society, with a large range of cultures 
and lifestyles at different stages of epidemiological transition. In all 
sub-populations, cardiovascular disease is a major cause of morbidity 
and mortality. Every day, approximately 80 people die of myocardial 
infarction or heart failure, while another 60 die due to stroke.4 
The INTERHEART Africa study indicated that more premature 
acute myocardial infarctions occur in sub-Saharan Africa than in 
any other of the 52 countries participating in the INTERHEART 
study.5,6 This statistic reflects a lack of prevention, early detection 
and effective management of cardiovascular risk factors in the 
countries of this region.5 In particular, in the black population, with 
increasing urbanisation and adoption of an unhealthy lifestyle, the 
prevalence of CVD and the incidence of premature death are likely to 
continue to increase.4 Consequently, the timely institution of lifestyle 
modification, early diagnosis and effective management of CVD risk 
factors are essential to curb the epidemic of CVD that has been seen 
in other countries.5  
2. When to use the cardiovascular risk 
score
2.1 Very high-risk individuals do not require risk 
scoring
Individuals who are considered to be at very high risk of cardiovascular 
events are listed in Table 1. Patients in this group DO NOT 
require cardiovascular risk scoring, because the risk score will be an 
underestimate in these settings.
2.2 Individuals who do not fall into the very high-risk 
category
Risk scoring using well-documented key risk factors is appropriate 
to estimate the total cardiovascular risk in asymptomatic adults. 
Furthermore, risk scoring is especially important in individuals with 
the following:
•	 hypertension and/or on antihypertensive medication
•	 smoking: cigarette smoking is defined as any cigarette smoking 
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ACS acute coronary syndromes 
ALT alanine aminotransferase 
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CVD cardiovascular disease
GFR glomerular filtration rate
HDL-C high-density lipoprotein cholesterol
LDL-C low-density lipoprotein cholesterol
hsCRP high-sensitivity C-reactive protein 
Lp(a) lipoprotein (a) 
MI myocardial infarction
TC total cholesterol
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TLC therapeutic lifestyle change
ULN upper limit of normal
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in the past month or a history of 20 cigarettes per day for 10 
years (10 pack years)
•	 BMI ≥30 kg/m2 or waist circumference >94 cm for men, >80 
cm for women
•	 family history of premature CVD (male before 55 years of age, 
female before 60 years)
•	 auto-immune chronic inflammatory disease, e.g. rheumatoid 
arthritis, systemic lupus erythematosus, psoriasis.
3. When to start screening
In South Africa, because the prevalence of familial 
hypercholesterolaemia is as high as 1 in 100 in some communities, 
each individual should be tested, preferably with a full lipogram or 
at least TC/LDL-C, at least once in young adulthood (from 20 years 
of age). Particular attention should be paid to individuals with other 
risk factors for CVD.
4. How to screen: using the 
Framingham Risk Score
The European guidelines use the Systematic Coronary Risk Estimation 
(SCORE) system to estimate cardiovascular risk. Because this scoring 
system is based on an exclusively European population, it may not 
accurately reflect coronary risk in South Africa. While it is recognised 
that it would be impossible to accurately estimate risk in all South 
African subpopulations with a single data set, the Adult Treatment 
Panel (ATP) III Framingham risk tables,7 which provide an estimate 
of the 10-year risk of CHD, have been validated in white and black 
populations in the USA and are transportable to other culturally 
diverse populations. Consequently, we considered this approach to 
be more appropriate for South Africa. Nevertheless, these risk tables 
are likely to underestimate risk in South African black and Indian 
patients. The Framingham CHD tables may also underestimate 
total CVD risk in middle-aged and older women, whose risk of 
stroke and heart failure is typically higher than that of CHD. Even 
when multiple elevated risk factors are present, it is difficult for a 
woman younger than 75 years to exceed a 10% predicted risk for 
CHD, precluding her from qualification for more aggressive CVD 
prevention.8 Consequently, more recent Framingham equations 
predict 10-year total CVD risk (including CHD, stroke, transient 
ischaemic attack and heart failure).8,9 
The updated Framingham CVD risk tables for men and women 
and an algorithm for management and cholesterol goals have been 
incorporated into these recommendations (Appendix 1).
5. Measuring lipids
5.1 Low-density lipoprotein cholesterol 
LDL-C is preferred when deciding on treatment and assessing its 
effect. LDL-C is used in preference to other tests as it is modifiable 
by treatment and the beneficial effects of lowering LDL-C are known. 
LDL-C may be measured directly or calculated from the Friedewald 
equation (in mmol/l) (LDL-C = TC – HDL-C – TG/2.2), provided the 
triglycerides do not exceed 4.5 mmol/l.
5.2 Total cholesterol
Once the relationship between on-treatment TC and LDL-C is 
known, it may be appropriate to monitor TC only. TC may be used 
as an alternative for screening, risk assessment and monitoring of 
treatment efficacy if there are cost constraints or if there is difficulty 
in obtaining either direct or indirect LDL-C values. 
Equivalent target values for TC are:
•	 TC = 4.5 mmol/l is approximately equivalent to LDL-C = 2.5 
mmol/l
•	 TC = 4.0 mmol/l is approximately equivalent to LDL-C = 1.8 
mmol/l.
If TC values remain uncontrolled and LDL-C measurement is 
unavailable, the patient should be referred to a specialist physician.
5.3 Cost-effective testing
A full lipogram (TC, HDL-C, LDL-C and triglycerides) is 
recommended for initial diagnosis of dyslipidaemia. In patients 
with pure hypercholesterolaemia, LDL-C alone is adequate for 
follow-up, but a full lipogram is recommended where increased 
LDL-C is not the only abnormality in the lipid profile. After 
initiating TLC alone, follow-up testing should be performed every 
6 months. After initiating pharmacotherapy, changing the dose or 
changing the specific drug prescribed, testing should be repeated 
at 8 (±4) weeks and thereafter, once the patient is at goal, every 6 
months. 
5.4 Point-of-care finger prick testing
Various point-of-care tests are available. They provide various 
results, ranging from TC alone to a full lipogram. Where finger prick 
testing is performed, the facility should ensure that adequate quality 
controls are in place, that the test strips and devices are stored under 
appropriate conditions of temperature, humidity and light, and that 
precautions are taken to perform the test properly, with an adequate 
blood sample volume and without contamination.10 The finger 
should not be squeezed or ‘milked’, as this will give inaccurate results. 
Finger prick testing is appropriate for screening and follow-up to 
determine where advice on lifestyle intervention is required (e.g. TC 
>5 mmol/l), but is not appropriate to commit a patient to a lifetime 
of therapy. Where a screening finger prick TC measurement is high 
(>5 mmol/l), the patient should be encouraged to discuss their 
finger prick screening result with their doctor, who should have a 
full laboratory-performed fasting lipogram done and then perform 
a full cardiovascular risk assessment. Because inappropriately low 
results are a concern, TC <2.5 mmol/l on a finger prick test should 
be confirmed. Finger prick testing that measures TC alone will not 
detect raised triglycerides.
5.5 Additional testing
The use of novel biomarkers of CVD (e.g. hsCRP) and imaging 
technologies (e.g. coronary calcium scoring, carotid intima-media 
thickness) is not recommended routinely and should be reserved to 
refine risk assessment in patients considered to be at moderate risk 
where there is uncertainty about whether to initiate drug therapy.8 It 
should be noted that hsCRP is a nonspecific inflammatory marker 
that may be elevated from many causes (e.g. acute infections or 
non-infectious inflammatory disorders). Measuring Lp(a) is only 
appropriate in HIGH CVD risk subjects and/or when there is a family 
Table 1. Subjects considered to be at very high risk of cardio-
vascular events
●   Established atherosclerotic disease, i.e.
•			coronary	artery	disease
•			cerebrovascular	disease
•			peripheral	arterial	disease
●   Type 2 diabetes
●   Type 1 diabetes with micro-albuminuria or proteinuria
●   Genetic dyslipidaemia, e.g. familial hypercholesterolaemia
●   Chronic kidney disease (GFR <60 ml/min/1.73 m2)
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history of premature CVD. When Lp(a) is used as a risk marker, the 
cut-off value is >50 mg/dl. 
5.6 Secondary dyslipidaemias
Dyslipidaemia may occur in response to another condition or 
treatment. Table 2 lists those encountered most commonly. The 
appropriate diagnostic tests should be performed when secondary 
dyslipidaemia is suspected and the underlying abnormality treated.
6. Strategy for intervention
The risk levels determined for the SCORE system refer to the 10-year 
risk of a fatal CVD event, whereas the Framingham scoring system 
refers to the 10-year risk of any CVD event. Risk thresholds for the 
Framingham score are therefore approximately 3 times those for 
SCORE.
Table 3 sets out the recommended appropriate intervention 
strategies according to the percentage risk calculated from the 
Framingham risk score and the LDL-C value obtained.
7. Treatment targets
Although we recommend the use of the Framingham risk charts 
to estimate cardiovascular risk, the management of patients, once 
risk has been determined, and the goals of therapy, are those of the 
European guidelines.
LDL-C goals for patients at different levels of Framingham risk are 
listed in Table 4. 
8. Management of dyslipidaemia
Because the total cardiovascular risk is the product of a number 
of risk factors, the treatment of dyslipidaemia must always be seen 
within the broader framework of cardiovascular disease prevention.
8.1 Lifestyle modification
It should be emphasised that the cornerstone of any programme to 
reduce cardiovascular risk is TLC (healthy diet, regular exercise). In 
order for the changes to be sustainable, dietary and exercise advice 
must be practical and tailored specifically to the individual’s personal 
and cultural preferences.11 Diets may need to be modified for people 
with unusual or specific disorders (e.g. hypertriglyceridaemia) and 
referral to a dietician and fitness professional is encouraged. An 
example of lifestyle and dietary advice that is relevant to the South 
African population is listed in Appendix 2.
8.2 Dietary supplements
Epidemiological and interventional studies support the role of 
healthy dietary choices as a whole to help reduce the risk of 
cardiovascular events. However, insufficient evidence exists 
to recommend the use of dietary supplements in patients with 
dyslipidaemia. While some dietary supplements have been shown 
to influence plasma lipids, there are no outcomes data that show 
benefits with regard to CVD prevention. Conversely, there is evidence 
that some supplements may be harmful to health and may interact 
with prescription medicines.12,13 Consumers should be advised to 
beware of unsubstantiated advertising claims relating to long-term 
health benefits. 
Although there are no known risks associated with its use, the 
routine use of coenzyme Q10 to reduce statin-related myalgia or 
myopathy is not supported by systematic reviews of the medical 
literature.14,15 
8.3 Statin therapy
Statins have demonstrated effectiveness in both primary and 
secondary prevention. The effect is dependent on the extent to 
which LDL-C is lowered and not on the type of statin used. At their 
Table 2. Secondary causes of dyslipidaemia
Diabetes mellitus
Hypothyroidism
Liver disease
Renal disease, e.g. nephrotic syndrome
Alcohol excess
Medications:
•			progestins
•			steroids
•			antiretroviral	agents
•			retinoids
Table 3. Intervention strategies as a function of Framingham total CVD risk score and LDL-C levels3*
Total CVD risk score†
LDL-C levels
<1.8 mmol/l 1.8 - <2.5 mmol/l 2.5 - 4.9 mmol/l >4.9 mmol/l
<3%
Low risk
No lipid intervention No lipid intervention Lifestyle intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
3 - 15%
Moderate risk
Lifestyle intervention Lifestyle intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if 
uncontrolled
15 - 30%
High risk
Lifestyle intervention, 
consider drug‡
Lifestyle intervention, 
consider drug‡
Lifestyle intervention 
and immediate drug 
intervention
Lifestyle intervention 
and immediate drug 
intervention
>30%
Very high risk
Lifestyle intervention, 
consider drug‡
Lifestyle intervention 
and immediate drug 
intervention
Lifestyle intervention 
and immediate drug 
intervention
Lifestyle intervention 
and immediate drug 
intervention
*Based on Table 3 from Reiner Ž, et al., Eur Heart J 2011;32:1769-1818.3
†Based on the Framingham CVD risk tables.9
‡In patients with MI, statin therapy should be considered regardless of LDL-C levels.
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maximum doses, the various statins differ in their capacity to lower 
LDL-C. 
For every mmol/l reduction in LDL-C there is a:
•	 10% reduction in mortality
•	 20% reduction in all-cause morbidity
•	 23% reduction in major cardiac events
•	 17% reduction in stroke.
The effect of statin therapy is similar in all patient subgroups and 
becomes significant after 1 year, increasing progressively thereafter.
8.4 High-dose simvastatin treatment
Although the incidence of myopathy is very low for all the statins, it 
is approximately 3 times as high with 80 mg simvastatin compared 
with maximum doses of atorvastatin and rosuvastatin. Accordingly, 
the American Food and Drug Administration (FDA) has mandated 
safety-labelling changes for medicines containing simvastatin, which 
include the following recommendations:16
•	 The use of 80 mg simvastatin should be restricted to those who 
have been using the dose chronically (longer than 12 months), 
without signs or symptoms of myopathy.
•	 Patients who are using simvastatin 80 mg and who need to start 
taking another drug that may interact with simvastatin should 
be switched to an alternative statin with a lower risk of drug 
interactions, such as rosuvastatin or atorvastatin.
•	 Patients who do not reach their LDL-C goal with 40 mg 
simvastatin should be switched to an appropriate alternative 
more potent statin with a lower potential for myopathy.
•	 To reduce the incidence of myopathy:
•	 do not exceed 10 mg simvastatin with amiodarone, verapamil, 
or diltiazem 
•	 do not exceed 20 mg simvastatin with amlodipine 
•	 simvastatin is contraindicated with azole antifungals, 
macrolide antibiotics, HIV protease inhibitors, gemfibrozil, 
cyclosporine and danazol.
8.5 Statin toxicity
When used in appropriate patients, statins are remarkably safe 
drugs and the benefits of cardiovascular protection far outweigh 
the potential for toxicity. However, patients should be encouraged 
to make and sustain healthy lifestyle choices and the lowest dose of 
statin to achieve LDL-C target should be used.
8.5.1 Statin-related myalgia and rhabdomyolysis
The presence of any musculoskeletal pain should be documented 
before starting statin therapy to facilitate the recognition of statin-
induced myalgia during treatment. 
A CK measurement prior to commencing statin treatment is 
recommended. Statins should not be started if the CK is >5 times 
the ULN. Routine CK monitoring is not necessary during treatment, 
unless the patient develops myalgia. Increased vigilance regarding 
CK and myopathy is necessary in the elderly, in those on concomitant 
interfering treatment or on multiple medications, and in the presence 
of liver or renal disease.
If myalgia develops and the CK is >5 times the ULN: 
•	 stop treatment
•	 check renal function
•	 monitor CK every 2 weeks
•	 consider causes of transient CK elevation, e.g. exercise
•	 consider alternative causes of myopathy.
If myalgia develops and the CK is <5 times the ULN:
•	 monitor symptoms
•	 monitor CK regularly.
If the CK is <5 times the ULN and there are no muscle symptoms:
•	 continue statin
•	 alert patient to report symptoms
•	 consider monitoring CK.
The incidence of rhabdomyolysis is very low.
In patients who are intolerant to statin therapy, potent statins, such 
as atorvastatin or rosuvastatin, may be used on alternate days (e.g. 
Monday, Wednesday, Friday) or even less frequently to reduce side-
effects.17 Alternatively, a combination therapy of a low-dose statin 
with a lipid-lowering drug of another class (e.g. ezetimibe) can be 
considered.
8.5.2 Statin-induced rises in alanine aminotransferase 
Baseline ALT measurement should be performed before initiating 
treatment with a statin. If the ALT is normal, it does not need to 
be repeated. Raised ALT does not exclude statin therapy, where 
treatment should be individualised. Alternative reasons for raised 
ALT (e.g. haemochromatosis, fatty liver) should be investigated 
where necessary.
If the ALT is raised <3 times the ULN while on treatment, continue 
the statin and recheck ALT in 4 - 6 weeks. If the ALT is raised >3 
times the ULN on treatment, stop the statin and repeat ALT in 4 - 6 
weeks. Cautious reintroduction of the statin can be considered once 
the ALT has returned to normal.
8.5.3 New-onset diabetes
Recent meta-analyses have demonstrated a very small increase in 
the risk of new-onset diabetes associated with statin use, notably 
in patients treated with intensive-dose statin therapy and in older 
patients.18,19 However, this small potential adverse risk is outweighed 
by the absolute reduction in CV events and should not discourage 
initiation of statin therapy.3,19,20 
8.6 Scheme for introducing statin treatment
•	 First evaluate the risk.
•	 Involve the patient in CV risk management decisions.
•	 Identify the appropriate LDL-C target.
•	 Calculate % reduction in LDL-C required to reach target. 
•	 Choose the statin (and dose) able to achieve the desired 
reduction (Table 5).
Table 4. LDL-C treatment targets
Total Framingham CVD risk (%) ESC/EAS risk classification ESC/EAS LDL-C target
<3 Low risk <3.0 mmol/l
3 - 15 Moderate risk <3.0 mmol/l
15 - 30 High risk <2.5 mmol/l
>30 Very high risk <1.8 mmol/l
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•	 It is mandatory to up-titrate the dose to achieve the LDL-C 
target.
•	 If target is not reached at maximal dose, consider a more potent 
statin or add a lipid-lowering drug from another class.
•	 The final statin choice will be influenced by concomitant 
conditions, concomitant drug therapy and tolerability.
8.7 Other cholesterol-lowering agents
The cholesterol absorption inhibitor ezetimibe in combination 
with simvastatin was shown to reduce major atherosclerotic events 
in patients with advanced chronic kidney disease.22 Although 
no other outcome studies have been completed, ezetimibe is 
recommended:
•	 as second-line treatment in combination with a statin when the 
LDL-C target is not reached at the highest tolerated statin dose
•	 when there is intolerance to statins
•	 when there is a contraindication to a statin.
Bile acid sequestrants and nicotinic acid have cholesterol-
lowering properties. They may occasionally be useful alone or 
in combination with statin therapy. However, their side-effects 
limit wider application.
Table 5. Practical guide to initiating statins depending on baseline LDL-C and target LDL-C values* 
Starting LDL-C 
(mmol)
Goal: <1.8 mmol/l Goal: <2.5 mmol/l Goal: <3.0 mmol/l
% reduction 
required Statin dose
% reduction 
required Statin dose
% reduction 
required Statin dose
>6.2 >70†
Rosuvastatin 40 mg 
Atorvastatin 80 mg
>60†
Rosuvastatin 40 mg 
Atorvastatin 80 mg
>55
Rosuvastatin 40 mg 
Atorvastatin 80 mg
5.2 - 6.2 65 - 70†
Rosuvastatin 40 mg 
Atorvastatin 80 mg
50 - 60
Rosuvastatin 20 mg 
Atorvastatin 40 mg
40 - 55
Rosuvastatin 10 mg 
Atorvastatin 20 mg
4.4 - 5.2 60 - 65†
Rosuvastatin 40 mg 
Atorvastatin 80 mg
40 - 50
Rosuvastatin 10 mg 
Atorvastatin 20 mg
Simvastatin 40 mg
30 - 45
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 20 mg 
Lovastatin 40 mg
Fluvastatin 80 mg
3.9 - 4.4 55 - 60
Rosuvastatin 40 mg
Atorvastatin 80 mg 35 - 40
Rosuvastatin 5 mg 
Atorvastatin 10 mg
Simvastatin 20 mg 
Lovastatin 40 mg 
Fluvastatin 80 mg
25 - 30
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg 
Lovastatin 20 mg
Pravastatin 40 mg
Fluvastatin 80 mg
3.4 - 3.9 45-55
Rosuvastatin 10 mg
Atorvastatin 40 mg 25 - 35
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg 
Lovastatin 20 mg
Pravastatin 40 mg
Fluvastatin 80 mg
10 - 25
Any statin at lowest 
dose
2.9 - 3.4 35 - 45
Rosuvastatin 5 mg 
Atorvastatin 10 mg
Simvastatin 20 mg 
Lovastatin 40 mg 
Fluvastatin 80 mg
10 - 25
Any statin at lowest 
dose
<10
Any statin at lowest 
dose
2.3 - 2.9 22 - 35
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg 
Lovastatin 10 mg
Pravastatin 20 mg
Fluvastatin 40 mg
<10
Any statin at lowest 
dose
-
1.8 - 2.3 <22
Rosuvastatin 5 mg
Atorvastatin 10 mg
Simvastatin 10 mg 
Lovastatin 10 mg
Pravastatin 20 mg
Fluvastatin 40 mg
- -
*Based on weighted average of pooled analysis at starting dose. Dose should be titrated according to response. 
†Maximum LDL-C reduction achievable with high-dose statin monotherapy is 50 - 60%. To achieve a reduction in LDL-C of >60%, another cholesterol-lowering agent in addition to statin therapy 
may be required.
Adapted from Reiner Ž, et al., Eur Heart J 2011;32:1769-18183 and Weng T-C, et al., J Clin Pharm Ther 2010;35:139-151.21
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8.8 Treatment directed at other components of the lipid 
profile
Whereas low levels of HDL-C and high levels of TG are undoubtedly 
associated with a higher cardiovascular disease risk, no currently 
available treatment directed at reversing these changes has been 
shown to significantly benefit cardiovascular outcome. 
A high triglyceride level, particularly if >10 mmol/l, can result in 
acute pancreatitis and should be treated without delay.
9. Special circumstances
9.1 Metabolic syndrome
The European Guidelines recognise the importance of identifying 
patients with the metabolic syndrome, who are at increased risk of 
cardiovascular disease. The presence of the syndrome approximately 
doubles the risk of cardiovascular disease. Lifestyle changes, 
particularly reducing body weight and increasing physical activity, 
are the cornerstone of management of the metabolic syndrome.23
9.2 Acute coronary syndromes 
A lipid profile should be obtained at the time of admission in patients 
presenting with ACS. They should be treated with high-dose statin 
therapy during their acute care and the statin dose should be adjusted 
at the time of discharge according to the admission lipid profile.
9.3 HIV infection
Dyslipidaemia frequently accompanies HIV and may be aggravated 
by ARVs. While there is limited information, particularly in South 
Africa, it is important to measure lipids in patients with HIV and 
estimate their CVD risk, and a full lipogram should be performed 
before initiating ARV treatment. The Framingham tables will 
generally underestimate CVD risk in this population. In patients 
with high lipid levels already on ARV treatment, switching to an 
alternative ARV and cautious use of a statin or fibrate as necessary 
should be considered. Simvastatin is contraindicated in patients using 
protease inhibitors.
9.4 Unusual conditions
Unexplained cutaneous or tendinous deposits (xanthomata), 
very premature vascular disease, some endocrine, metabolic and 
neurological disorders constitute reasons for referral. Unusually low 
TC (<2.5 mmol/l), LDL-C (<1.5 mmol/l), HDL-C (<0.7 mmol/l) or 
unusually high TG (>10mmol/l), TC (>15 mmol/l), LDL-C (>12 
mmol/l), HDL-C (>2.5 mmol/l) also deserve special consideration.
10. Conclusions: implementation of 
the 2011 guidelines
In order to implement the guidelines, we propose a simple chart that 
has been updated to accommodate the new Framingham CVD risk 
tables (Appendix 1). The chart is a guide to management only and 
should not replace an individualised assessment and treatment plan 
based on the clinical judgement of the doctor. We encourage the 
reader to read the 2011 European guidelines in full, which may be 
accessed on the ESC website www.escardio.org/guidelines. We hope 
that dissemination of these guidelines will go some way towards 
helping to reduce the burden of CVD in South Africa.
11. Mechanism of guideline 
preparation
In October 2011 a broad-based group of participants from the medical 
and allied health community, medical funders, pharmaceutical 
companies, the Department of Health, the Board of Health Funders 
and the Heart and Stroke Foundation met together with Professor 
Marja-Riitta Taskinen in Sandton, Johannesburg, to examine and 
discuss the joint ESC/EAS dyslipidaemia guidelines. Professor 
Taskinen is a co-author and Task Force Member of these guidelines 
and attended on behalf of the European Atherosclerosis Society. 
The following day a writing committee met to construct the South 
African Consensus Document.
Additional delegates attending the Dyslipidaemia Guidelines 
Meeting Discussion Group were Dr A Amod (SEMDSA), Ms G 
Bartlett (Universal Health), Ms U Behrtel, Dr S Bhana (Netactive), 
Ms M Campbell (Discovery), Mr D Craythorne (Cipla), Mr A 
Dansay (PharmaDynamics), Ms L Doms (Medscheme), Ms A du 
Plessis (Vital Health), Ms U du Preez (Astra Zeneca), Dr R Espaillat 
(Abbott Laboratories), Dr Craige Golding (Solal Laboratories), Ms 
K Jamaloodien (National Department of Health), Dr D Katzman 
(MSD), Dr S Kahn, Mr M Lambert (Aspen), Dr M Makotoko, Mr M 
Mashego (Adcock Ingram), Ms Y Misra (MediKredit), Dr M Mpe, 
Dr V Mungai-Singh (Heart and Stroke Foundation), Ms L Naidoo 
(Sanlam Healthcare), Ms N Nel, Dr R Patel (Board of Healthcare 
Funders), Ms D Pithey (MSD), Mr J Rall (Ranbaxy), Dr J Snyman 
(Agility Global Health Solutions), Dr M Sussman (SA Heart), Dr 
M Swanepoel (Medihelp), Professor J P van Niekerk (South African 
Medical Journal), Ms L Xiphu (QUALSA/Metropolitan).
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Appendix 1. Cardiovascular risk stratification
Framingham 10-year risk assessment chart for patients without diabetes
Risk of CVD: coronary heart disease, stroke, peripheral artery disease, or heart failure
Estimate of 10-year risk of CVD for men Estimate of 10-year risk of CVD for women
Age (yrs) Points Age (yrs) Points
30 - 34 0 30 - 34 0
35 - 39 2 35 - 39 2
40 - 44 5 40 - 44 4
45 - 49 6 45 - 49 5
50 - 54 8 50 - 54 7
55 - 59 10 55 - 59 8
60 - 64 11 60 - 64 9
65 - 69 12 65 - 69 10
70 - 74 14 70 - 74 11
75 years or older 15 75 years or older 12
Total cholesterol (mmol/l) Points Total cholesterol (mmol/l) Points
<4.10 0 <4.10 0
4.10 - 5.19 1 4.10 - 5.19 1
5.2 - 6.19 2 5.2 - 6.19 3
6.20 - 7.20 3 6.20 - 7.20 4
>7.20 4 >7.20 5
HDL-cholesterol (mmol/l) Points HDL-cholesterol (mmol/l) Points
≥1.50  -2 ≥1.50  -2
1.30 - 1.49  -1 1.30 - 1.49  -1
1.20 - 1.29 0 1.20 - 1.29 0
0.90 - 1.19 1 0.90 - 1.19 1
<0.90 2 <0.90 2
Systolic BP – untreated (mmHg) Points Systolic BP – untreated (mmHg) Points
<120  -2 <120  -3
120 - 129 0 120 - 129 0
130 - 139 1 130 - 139 1
140 - 159 2 140 - 149 2
≥160 3 150 - 159 4
≥160 5
Systolic BP – on 
antihypertensive treatment 
(mmHg)
Points Systolic BP – on 
antihypertensive treatment 
(mmHg)
Points
<120 0 <120  -1
120 - 129 2 120 - 129 2
130 - 139 3 130 - 139 3
140 - 159 4 140 - 149 5
≥160 5 150 - 159 6
≥160 7
Smoker Points Smoker Points
No 0 No 0
Yes 4 Yes 3
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Points total for men Points total for women
Points total 10-year risk (%) Points total 10-year risk (%)
-3 or less <1 -2 or less <1%
-2 1.1 -1 1.0
-1 1.4 0 1.1
0 1.6 1 1.5
1 1.9 2 1.8
2 2.3 3 2.1
3 2.8 4 2.5
4 3.3 5 2.9
5 3.9 6 3.4
6 4.7 7 3.9
7 5.6 8 4.6
8 6.7 9 5.4
9 7.9 10 6.3
10 9.4 11 7.4
11 11.2 12 8.6
12 13.2 13 10.0
13 15.6 14 11.6
14 18.4 15 13.5
15 21.6 16 15.6
16 25.3 17 18.1
17 29.4 18 20.9
18 or more >30 19 24.0
20 27.5
20 or more >30
Point totals indicate the 10-year risk of cardiovascular disease (coronary, cerebrovascular and peripheral arterial disease, and heart failure).
 Low risk   Moderate risk   High risk   Very high risk
Adapted from D’Agostino RB, et al., General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 
2008;117:743-7539 and Mosca L, et al., Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A 
guideline from the American Heart Association. Circulation 2011;123:1243-1262.8
Management and cholesterol goals according to Framingham risk score
Category 1: Individuals considered to be at very high risk who do not need scoring
1. Established atherosclerosis
•	 coronary heart disease
•	 cerebrovascular disease
•	 peripheral vascular disease
2. Type 2 diabetes*
3. Type 1 diabetes with target organ damage
4. Chronic kidney disease (GFR <60 ml/min/1.73 m2)
5. Genetic dyslipidaemias (e.g. familial hypercholesterolaemia)
*In patients with type 2 diabetes younger than age 40 years or with duration of diabetes <10 years and no other CVD risk factors, the LDL-C 
target is <2.5 mmol/l.
Goal:†
LDL cholesterol <1.8 mmol/l**
**and/or a >50% LDL-C reduction when the LDL-C target cannot be achieved
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Category 2:‡ Risk scoring required – use the Framingham risk tables§
                                               Use correct gender table:                     Score:
                 1. Age                    1. ________
                                       2. Total cholesterol¶                    2. ________
                                            3. Non-smoker/smoker                    3. ________
                        4. HDL-C                    4. ________
                            5. Systolic BP                    5. ________
†Pharmacological treatment is required if LDL cholesterol remains above these levels despite lifestyle modification. At present statins are first-line 
drugs for lowering LDL cholesterol.
‡Secondary causes of dyslipidaemia should be excluded before progressing to risk assessment.
§See limitations of Framingham Risk Assessment Score on this page.
¶Total cholesterol level is used to assign risk score and may be used for follow-up cholesterol measurement in patients on drug therapy, but LDL 
cholesterol is the target of treatment.
Limitations of the Framingham Risk Assessment Score charts
1. Patients who are classified in the very high-risk category do not require further risk scoring for management decisions. Risk will also be 
underestimated in patients who have a markedly elevated single risk factor (e.g. severe hypertension: systolic BP >180 mmHg and/or diastolic BP 
>110 mmHg), or associated target organ damage.
2. Severe hypercholesterolaemia and hypertriglyceridaemia: The Framingham risk assessment chart is only accurate up to total cholesterol values 
of 7.25 mmol/l and cannot be used for patients with TC levels above this value. It also does not apply to hypertriglyceridaemia (triglyceride >5 
mmol/l).
3. Family history of early atherosclerotic disease is not taken into account. Clinicians should use their judgement in deciding whether to place a 
patient with an impressive family history in the high-risk category regardless of their Framingham score. 
4. Despite these factors being important risk factors for CVD, impaired glucose tolerance and abdominal obesity are not taken into account in the 
risk score. 
LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density 
lipoprotein cholesterol; TG = triglyceride; CHD = coronary heart 
disease; CVD = cardiovascular disease; BP = blood pressure.
Conversion from mg/dl
Cholesterol:
mmol/l = mg/dl × 0.0259
mg/dl = mmol/l × 38.6
Triglyceride:
mmol/l = mg/dl × 0.0113
mg/dl = mmol/l × 88.5
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Appendix 2. South African Heart Association/LASSA guidelines for lifestyle modification for patients with dyslipidaemia
1. Stop smoking and avoid exposure to environmental tobacco smoke.
2. Increase your physical activity. Try to do exercise of moderate intensity, such as brisk walking, for at least 30 minutes on all or most days of 
the week.
3. Achieve and maintain ideal body weight.
4. Reduce your intake of saturated fats, trans-fats and cholesterol. Avoid eating fatty meats, processed meats, chicken skin, processed meats, 
confectionery such as pies, pastries and cookies, fast foods, deep-fried potato chips (‘slap chips’), butter, ghee, cream, hard cheeses and salty 
crackers.
5. Replace saturated fats with unsaturated fats. Avoid the use of hard margarines, butter and ghee for cooking or adding to food. Use 
unsaturated fats such as canola oil, olive oil and sunflower oil for cooking. Use oils sparingly and avoid all deep-frying of food. Remove all 
visible fat before cooking. Increase your intake of all types of fish, especially oily fish such as sardines and salmon, to a minimum of twice a 
week.
6. Increase your intake of fibre, especially soluble fibre. Include foods such as oats, fresh fruit and legumes (dry beans, soya beans, chickpeas, 
all types of lentils). Include a minimum of five portions of fresh fruit and vegetables in your daily diet.
7. Replace all refined carbohydrate types of foods with foods high in fibre, such as whole grains. Avoid eating products made from white flour, 
such as white bread and rolls, pizzas, vetkoek, samoosas, pies, prego rolls and bakery items such as cakes and biscuits. Incorporate whole-
grain foods such as oats, barley, stampkoring (pearl wheat), crushed wheat, samp and beans, brown rice, brown/wild rice, whole-grain 
breakfast cereals, health and seed breads.
8. Avoid foods high in free sugars (sucrose, high-fructose corn syrup, fructose) such as sweets, chocolates, all fizzy soft drinks, fruit juices, all 
flavoured and sweetened waters, low-fat sweetened milky drinks.
9. If you consume alcohol, do so in moderation – no more than 2 drinks for men and 1 drink for women per day.
10. Avoid adding salt to food after cooking. Choose and prepare foods with little or no salt by using more herbs and spices.
11. For dietary lifestyle intervention all patients should ideally be referred to a registered dietician. 
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